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Lack of a vaccine for infants and immunosuppression after infection are problems associated with measles
virus (MV). Because interleukin (IL)–12 has been used successfully as a vaccine adjuvant and because inhibition
of IL-12 expression has been associated with immunosuppression during measles, the addition of IL-12 may
enhance the immune response to MV. To determine the effect of IL-12 supplementation, rhesus macaques
were vaccinated with a recombinant MV expressing IL-12; these macaques had increased interferon-g pro-
duction by CD4+ T cells, decreased production of IL-4, and lower levels of MV-specific immunoglobulin G4
and neutralizing antibody. Lymphoproliferative responses to mitogen were not improved. IL-12 supplemen-
tation altered the T helper type 2 bias of the immune response after MV vaccination, had a detrimental effect
on the protective neutralizing antibody response, and did not improve other manifestations of immunosup-
pression. Reduced IL-12 levels are not the sole factor in MV-induced immunosuppression.
Two serious and interrelated problems define the ad-
verse effects of measles virus (MV) infection in devel-
oping countries. First, measles is an immunosuppres-
sive disease that leads to increased susceptibility to
infections with other pathogens, causing deaths world-
wide every year; there were 800,000 deaths attributed
to measles in 2000 [1]. Second, efforts to eliminate MV
are hampered by the fact that the current live attenuated
MV vaccine is poorly immunogenic in infants as a result
of interference of transplacentally acquired maternal
antibody with vaccine viral replication and immaturity
of the infants’ immune system [2, 3]. These problems
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may be linked, as suggested by the increased mortality
observed after administration of high-titer, live atten-
uated MV vaccines to infants in the 1990s. High-titer
vaccines overcame interference by transplacental anti-
body and immune immaturity, eliciting stronger anti-
body responses than regular vaccine, but may have led
to immunosuppression similar to that of wild-type in-
fection and increased mortality in female vaccine re-
cipients [4].
MV-induced immunosuppression is characterized by
transient lymphopenia during the viremic period [5],
prolonged inhibition of delayed-type hypersensitivity
responses in vivo [6, 7], decreased lymphocyte prolif-
eration to mitogens in vitro [8, 9], and polarization of
cytokine production toward type 2 (Th2) cytokines
(e.g., interleukin [IL]–4 [10]), which is associated with
a decrease in the type 1 (Th1)–inducing cytokine IL-
12 [11, 12]. In fact, reduced IL-12 production by MV-
infected antigen-presenting cells has been proposed as
a factor that leads to Th2 cytokine skewing and im-
munosuppression [13]. IL-12 is important in stimu-
lating Th1 CD4+ T cell responses [14], and its deficiency
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Figure 1. Measles virus (MV) expressing human interleukin (IL)–12
(MVIL-12). The MV genome and IL-12 genes comprising the MVIL-12 virus
are as follows: F, fusion; H, hemagglutinin; L, large polymerase protein
of MV; M, matrix; N, nucleocapsid; P, phosphoprotein; and the p40 and
p35 subunits of IL-12 separated by the internal ribosome entry site (IRES)
sequences of encephalomyocarditis virus [26].
leads to increased susceptibility to infections known to affect
patients with measles during convalescence [15, 16].
IL-12 has also been shown to affect antibody production
either directly, by interaction with B cells, or indirectly, by the
stimulation of T helper cells [17–19], and to promote interferon
(IFN)–g production by CD8+ T cells [20]. Consequently, IL-
12 has been proposed for use as an adjuvant for a variety of
experimental vaccines [21–24] and is particularly attractive for
use with live MV vaccines, because the addition of IL-12 during
administration of the live attenuated vaccine may overcome
the problems posed by maternal antibody interference and im-
maturity of the immune system in infants while preventing the
immunosuppression associated with high-titer vaccines.
Therefore, we engineered a recombinant MV vaccine strain
that stably expressed human IL-12 (functional in macaques
[25]) as the biologically active heterodimer p70 [26]. Rhesus
macaques were vaccinated with this virus and studied to de-
termine whether IL-12 supplementation could serve as an ad-
juvant for MV vaccination and/or abolish measles-associated
immunosuppression. Immune responses were compared with
those of monkeys vaccinated with the parent MV not expressing
IL-12 (MVtag).
MATERIALS AND METHODS
Virus. Recombinant MV expressing human IL-12 (MVIL-12)
was constructed from cloned Edmonton B DNA (MVtag), as
described elsewhere [26]. MVIL-12 contains an extra transcrip-
tion element, located between the H and large polymerase (L)
genes of MV, that consists of the genes for the p40 and p35
subunits of human IL-12 divided by an internal ribosome entry
site element from encephalomyocarditis virus (figure 1). MVIL-
12 was grown and assayed by plaque formation in Vero cells.
Animals and vaccination. Seven MV-seronegative rhesus
macaques, 1–2 years old, were obtained from the Johns Hopkins
University primate facility. A total of pfu of MVIL-12 (443 10
monkeys) or MVtag (3 monkeys) were injected intramuscularly.
At 14 months after vaccination, each of the monkeys was chal-
lenged with 104 TCID50 of the wild-type Bilthoven MV strain (a
gift from A. Osterhaus, Erasmus University, Rotterdam). Mon-
keys were chemically restrained with ketamine (1 mg/kg) during
all procedures.
All animal studies had the approval of and followed the
guidelines of the Johns Hopkins University Animal Care and
Use Committee.
Reverse-transcriptase polymerase chain reaction (RT-PCR)
and Southern-blot analyses. Total cellular RNA was extracted
from peripheral blood mononuclear cells (PBMCs) that61 10
had been stimulated for 48 h with phytohemagglutinin (4 mg/
mL PHA-P) using RNAStat 60 (Teltest) and was resuspended
in 20 mL of RNase-free water. A total of 15 mL of RNA was
converted into cDNA and amplified during a 1-step RT-PCR
(Invitrogen) by use of N-specific primers (5′-CATTACATCAG-
GATCCGG-3′ and 3′-CTACTCCGCCTGGTTATG-5′). After 40
cycles, 15 mL of the PCR product was separated by 1% agarose
gel electrophoresis. The PCR product was transferred overnight
onto a nylon membrane (Hybond-N; Amersham Pharmacia)
and was visualized by Southern-blot analysis by use of an in-
ternal N-specific digoxigenin-labeled probe (/5 Dig N/5′-GAG-
CCATCAGAGGAATCA-3′). Water was used as a negative con-
trol. The positive control was RNA obtained from MVtag virus
grown in Vero cells. Relative amounts of N product were as-
sessed by densitometry with the LAS-1000 Plus CCD camera
system and Image Gauge software (both from Fujifilm). The
lower limit of detection was 10 pg of MV N-gene RNA.
Antibody assays. EIAs to measure levels of MV-specific
IgG, IgG1, IgG2, and IgG4 were performed by use of lysates
of MV-infected Vero cells as antigen. H- and F-specific EIAs
were performed by use of lysates of L cells expressing either
the H or F glycoproteins (provided by T. F. Wild, INSERM,
Lyon, France), as described elsewhere [27, 28]. IgG subclasses
were measured by using monoclonal antibodies (MAbs) against
human IgG1, IgG2, and IgG4 (Binding Site). Neutralizing an-
tibody was measured by the ability of serially diluted plasma
to reduce plaque formation of MV on Vero cells by 50%, as
described elsewhere [29]. All assays were run in triplicate, and
the results were averaged. EIA values are expressed as the dif-
ference in absorbance between MV-specific immune serum and
nonimmune control serum.
Isolation of PBMCs and flow cytometry. PBMCs were
separated from heparinized blood by density centrifugation on
a Ficoll-Hypaque gradient (density, 1.077; Amersham). For in-
tracellular cytokine staining, 106 PBMCs were incubated with
60 ng/mL PMA (Sigma), 500 ng/mL ionomycin (Sigma), and
5 mL of GolgiStop (BD PharMingen) for 5 h, blocked with 100
mL of 20% monkey serum in RPMI 1640 medium, and incu-
bated for 15 min with 25 mg/mL fluorescein isothiocyanate–
conjugated mouse anti–human CD3 (clone SP34; BD Phar-
Mingen) and Cy-Chrome–conjugated mouse anti–human CD8
(clone RPA-T8; BD PharMingen) MAb or control mouse im-
munoglobulin (clone MOPC-21; BD PharMingen). A phyco-
erythrin-conjugated mouse anti–human IFN-g MAb (clone
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Figure 2. Reverse-transcriptase polymerase chain reaction and South-
ern-blot detection of measles virus (MV) in monkeys vaccinated with MV
expressing human interleukin (IL)–12 (MVIL-12) or parent MV not ex-
pressing IL-12 (MVtag). Lanes 1–4, N-gene RNA present in peripheral
blood mononuclear cells (PBMCs) derived from MVIL-12–infected mon-
keys; lanes 5–7, N-gene RNA present in PBMCs derived from MVtag-
infected monkeys. +, Positive control; , negative control; B, blank (lane
skipped).
Figure 3. Measles virus (MV)–specific antibodies produced by monkeys vaccinated with MV expressing human interleukin (IL)–12 (MVIL-12) or
parent MV not expressing IL-12 (MVtag). MV-specific IgG against total MV protein (A), H glycoprotein (E), and F glycoprotein (F), as measured by EIA.
B, MV-specific IgG1. C, MV-specific IgG4. D, MV-neutralizing antibody, as measured by plaque reduction. Symbols indicate geometric mean titers.
Error bars indicate SE. * . PRNT, plaque reduction neutralization titer.P ! .05
B27; BD PharMingen), control mouse immunoglobulin (clone
MOPC-21; BD PharMingen), or biotinylated anti–monkey
IL-4 (BioSource International), followed by phycoerythrin-
conjugated streptavidin (BioSource) was used to stain intra-
cellularly. All antibodies were used at saturating concentrations,
as defined by the manufacturer. Lymphocyte acquisition was
performed with a FACScalibur flow cytometer, and data were
analyzed by CellQuest software (both from Becton Dickinson
Immunocytometry Systems).
Lymphoproliferation and cytokine assays. PBMCs were
suspended at a concentration of 106 cells/mL in RPMI 1640
medium supplemented with 10% fetal bovine serum. Spon-
taneous and PHA-induced proliferation of PBMCs were mea-
sured after 72 h of culture, as described elsewhere [8, 9]. Data
are expressed in terms of the stimulation index (i.e., the ratio
of PHA-induced proliferation to spontaneous proliferation).
Supernatant fluids from PHA-stimulated PBMCs were collected
after 48 h, and levels of IFN-g and IL-4 were measured by EIA,
according to the manufacturer’s instructions (BioSource). In
addition, supernatant fluids from PBMCs stimulated with 1 mg/
mL Salmonella typhimurium lipopolysaccharide (LPS; Sigma)
and 300 IU/mL IFN-g (BD PharMingen) were collected after
24 h, and levels of IL-12 and IL-10 were measured by EIA
(BioSource). IL-12 levels in plasma were also measured by EIA
(BioSource).
Granzyme B assay. Cytotoxic T lymphocyte (CTL) activity
was assessed by measuring granzyme B activity in PBMCs, as
described elsewhere [30, 31].
Statistical analysis. Data between groups immunized with
either MVIL-12 or MVtag were compared by an unpaired Stu-
dent’s t test by Stat-View software (version 5.0.1; SAS Institute).
For plasma IL-12 levels, data from the MVIL-12 and MVtag
groups after vaccination were compared with baseline data from
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Figure 4. Cytotoxic T lymphocyte response and CD8+ T cell activity
in peripheral blood mononuclear cells from monkeys vaccinated with
measles virus (MV) expressing human interleukin (IL)–12 (MVIL-12) or
parent MV not expressing IL-12 (MVtag). A, Granzyme B activity reported
as absorbance (Abs) per milligram of total cellular protein. B, Change in
the percentages of PMA/ionomycin-stimulated CD3+/CD8+ T cells ex-
pressing intracellular interferon (IFN)–g after vaccination. Error bars in-
dicate SE.
Figure 5. Antibody and cytotoxic T lymphocyte responses to challenge
with wild-type virus in monkeys vaccinated with measles virus (MV)
expressing human interleukin (IL)–12 (MVIL-12) or parent MV not ex-
pressing IL-12 (MVtag). MV-specific IgG against H glycoprotein (A) and
F glycoprotein (B), as measured by EIA. C, MV-neutralizing antibody, as
measured by plaque reduction. D, Granzyme B activity reported as ab-
sorbance (Abs) per milligram of total cellular protein. Symbols indicate
geometric mean titers. Error bars indicate SE. PRNT, plaque reduction
neutralization titer.
the MVIL-12 and MVtag groups, respectively, by an unpaired
Student’s t test.
RESULTS
Use of IL-12 as an Adjuvant for MV Vaccination
Infectivity of MVIL-12 and MV-tag in macaques. Although
replication is delayed by 12 h, MVIL-12 grows to titers com-
parable to that of the parent MV in Vero cells [26]. To confirm
MVIL-12 replication in vivo, we assessed the relative amounts
of MV RNA in PBMCs by use of RT-PCR and Southern-blot
analysis. N-gene RNA in PBMCs was present in comparable
levels on day 7 in monkeys vaccinated with MVIL-12 and
MVtag virus (figure 2) but it was not detectable in PBMCs
obtained from any of the monkeys on day 0 or day 25 (data
not shown).
MV-specific antibody production after vaccination with
MVIL-12 and MVtag. All monkeys showed an increase in
MV-specific IgG that was first detected 14 days after vaccination
(figure 3A). Both MVIL-12 and MVtag recipients had detectable
MV-neutralizing antibody by day 14. However, neutralizing
antibody titers were significantly higher in MVtag-vaccinated
monkeys than MVIL-12–vaccinated monkeys (day 21, Pp
; day 42, ; figure 3D). Neutralizing antibodies.035 Pp .02
against MV are directed against both surface glycoproteins, H
and F. To determine whether the lower neutralization titers in
MVIL-12–vaccinated monkeys reflected an altered response to
one or both glycoproteins, H- and F-specific EIAs were per-
formed. Levels of IgG to H, the major neutralizing antigen,
were higher in the MVtag- than MVIL-12–vaccinated monkeys
(day 42, ; figure 3E). However, levels of IgG to the minorPp .01
neutralizing antigen F were higher and detected earlier in
MVIL-12–vaccinated monkeys (figure 3F).
To further characterize the nature of the antibody responses,
we examined the isotypes and IgG subclasses. IgG1 was the
primary IgG subclass produced in both groups but was present
at higher levels in MVIL-12–vaccinated monkeys than in
MVtag-vaccinated monkeys (figure 3B). MV-specific IgG4 (day
42, ) was detectable only in MVtag-vaccinated mon-Pp .0001
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Figure 6. Cytokines secreted by peripheral blood mononuclear cells (PBMCs) from macaques and in plasma at various times after vaccination with
measles virus (MV) expressing human interleukin (IL)–12 (MVIL-12) or parent MV not expressing IL-12 (MVtag). Cytokine levels were measured by EIA
in supernatant fluids of lipopolysaccharide /interferon (IFN)–g– or PHA-stimulated PBMCs after infection with MVIL-12 or MVtag, A, IL-12; B, IL-10;
C, IFN-g; D, IL-4; and E, IL-12 levels in plasma. Error bars indicate SE. * , day 14 and day 28 IL-12 levels vs. baseline IL-12 level (day 0) inP ! .05
MVIL-12–infected monkeys.
keys (figure 3C). MV-specific IgG2 and IgE were undetectable
in both groups (data not shown).
CTL responses and CD8+ T cell activity after vaccination
with MVIL-12 and MVtag. Because IL-12 enhances the lytic
capacity of CTLs, effector cells that assist in the clearance of
MV-infected cells [32], we measured granzyme B activity, a
correlate of CTL activity [30, 31], in extracts from PBMCs at
various times after vaccination (figure 4A). Granzyme B activity
decreased slightly in both groups during the first week after
vaccination (correlating with the lymphopenia) and peaked by
the end of the second week. The addition of IL-12 did not
augment this response.
CD8+ T cells were stained with fluorochrome-labeled anti-
bodies against CD8 and CD3 surface markers for specificity.
Because IL-12 also increases production of IFN-g by T cells
[20], which might help mediate an effective Th1 response
against MV, intracellular IFN-g levels were assessed, by use of
flow cytometry, in stimulated PBMCs derived from MVIL-12–
and MVtag-vaccinated monkeys. Like granzyme B activity, the
percentage of CD8+ T cells producing IFN-g initially decreased
in both groups and then peaked on day 14 (figure 4B). A higher
percentage of CD8+ T cells from MVIL-12–vaccinated ma-
caques were IFN-g positive, than from MVtag-vaccinated mon-
keys, but the difference was not statistically significant.
Challenge of macaques vaccinated with MVIL-12 and
MVtag with wild-type MV. To determine whether vaccina-
tion with supplemental IL-12 affected protection from chal-
lenge with wild-type virus, monkeys were challenged 14 months
after vaccination with a strain and dose of wild-type MV known
to produce measles in macaques [27, 28]. All macaques in both
groups were protected against MV challenge. None of the mon-
keys developed a rash or had evidence of viremia (data not
shown). The neutralizing antibody response after challenge re-
mained stable, which confirms the protective effect of vacci-
nation (figure 5C). No significant changes or differences were
observed in anti-H or anti-F antibody responses between
1558 • JID 2003:188 (15 November) • Hoffman et al.
Figure 7. Flow cytometric analysis of cytokine production in monkeys after vaccination with measles virus (MV) expressing human interleukin (IL)–
12 (MVIL-12) or parent MV not expressing IL-12 (MVtag). A, Forward scatter (FSC) and side scatter (SSC) plot of peripheral blood mononuclear cells
obtained from an MVtag-vaccinated monkey, after stimulation with PMA and ionomycin. B, Percentage of gated lymphocytes staining positive for CD3
antibody alone, and CD3 and CD8 antibodies combined. C, Percentage of CD3+/CD8 (CD4) T cells expressing intracellular IL-2 on day 10. D, Percentage
of CD3+/CD8+ (CD8) T cells expressing intracellular IL-2 on day 10. Time course of PMA/ionomycin-stimulated CD3+/CD8 T cells expressing intracellular
interferon (IFN)–g (D) and IL-4 (E) in or MVtag- or MVIL-12–infected monkeys. Error bars indicate SE. * .Pp .05
groups, and these responses correlated with the neutralizing
antibody response (figure 5A and 5B). CTL responses were
similar in both groups (figure 5D).
IL-12 Supplementation to Prevent MV-Associated
Immunosuppression
Cytokine secretion after vaccination with MVIL-12 and
MVtag. To examine the influence of supplemental IL-12 on
cytokine production, supernatant fluids of stimulated PBMCs
were assayed at various times after vaccination (figure 6). IL-
12 levels in supernatant fluids of PBMCs stimulated with IFN-
g and LPS were not affected by IL-12 supplementation and
were identical in both groups, whereas IL-10 increased in both
groups during convalescence (figure 6A and 6B). However,
plasma IL-12 levels in MVIL-12–vaccinated monkeys were sig-
nificantly higher (day 14, ; day 28, ), com-Pp .036 Pp .035
pared with baseline levels (MVIL-12, day 0), whereas plasma
IL-12 levels in MVtag-vaccinated monkeys did not change from
baseline (figure 6E).
IFN-g production in supernatant fluids of PHA-stimulated
PBMCs was maximal on day 7 in both groups (probably as-
sociated with NK cell activity) and increased again on day 14
only in MVIL-12–vaccinated monkeys (figure 6C). IL-4 was
detected more often in supernatant fluids of MVtag-vaccinated
macaques (figure 6D).
Flow cytometric analysis of CD4+ T cell cytokine production
after vaccination with MVIL-12 and MVtag. To assess in-
tracellular cytokine production in T cells after vaccination with
the 2 viruses, PBMCs from both groups of monkeys were stim-
ulated with PMA and ionomycin and stained for intracellular
IFN-g and IL-4. Because macrophages can express CD4 and
because NK cells can express CD8 in monkeys [33], CD4+ and
CD8+ T cells were identified during flow cytometric analysis
by staining for both CD3 and CD8 (figure 7). Cells in the gated
lymphocyte population (based on forward and side scatter
properties), which stained brightly with the CD8 antibody and
were positive for CD3 (CD3+/CD8+), were identified as CD8
T cells, and lymphocytes that were positive for CD3 and neg-
ative for CD8 (CD3+/CD8) were identified as CD4 T cells
(figure 7A and 7B). This method for identifying individual T
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Figure 8. Changes in lymphoproliferation and lymphocyte counts after
vaccination with measles virus (MV) expressing human interleukin (IL)–
12 (MVIL-12) or parent MV not expressing IL-12 (MVtag). A, Proliferation
of peripheral blood mononuclear cells after 72 h of culture, reported as
the stimulation index (SI) (i.e., the ratio of phytohemagglutinin-induced
proliferation to spontaneous proliferation). B, Lymphocyte counts. Error
bars indicate SE.
cell subsets provided a CD4:CD8 T cell ratio of ∼1.5:2, which
is comparable to that in humans. The restricted populations
were subsequently gated to evaluate cytokine production (figure
7C and 7D).
CD4+ T cells from both groups of monkeys increased pro-
duction of IL-4 on day 9 (figure 7F) and decreased below
baseline levels by day 35. The percentage of CD4+ T cells pro-
ducing IFN-g was significantly greater in the MVIL-12–vacci-
nated monkeys than in MVtag-vaccinated monkeys during the
period of viremia and, thus, during the period of MVIL-12
expression leading to IL-12 production ( ; figure 7E).Pp .05
Lymphocyte proliferation after vaccination with MVIL-12
and MVtag. To determine the effect of IL-12 on the functional
responsiveness of T lymphocytes after vaccination, we measured
the proliferation of PHA-stimulated and -unstimulated PBMCs
from MVIL-12– and MVtag-vaccinated monkeys (figure 8A).
Both groups exhibited a profound decrease in lymphoprolifer-
ative responses to mitogen on day 7, concurrent with lympho-
penia (figure 8B). Decreased proliferation persisted for at least
14 weeks and was not different between the 2 groups.
DISCUSSION
In the present study, we have examined the role of IL-12 as an
adjuvant in MV vaccination and as a supplement to prevent
MV-associated immunosuppression. Supplemental IL-12 led to
an increased percentage of CD4 T cells producing IFN-g but
had no effect on the CTL response or on the suppression of
lymphoproliferative responses after MV vaccination. Further-
more, supplemental IL-12 decreased the levels of neutralizing
and H-specific antibodies induced by MV vaccination. How-
ever, it did not abrogate vaccine-induced protection from chal-
lenge with wild-type MV.
IL-12 promoted a Th1 bias in the overall immune response,
because CD4 T cells were more likely to produce IFN-g in the
MVIL-12–vaccinated macaques than in the MVtag-vaccinated
macaques. In addition, fewer monkeys in the MVIL-12 group
than in the MVtag group had detectable IL-4 in supernatant
fluids of stimulated PBMCs. This was reflected in higher levels
of IgG1 and a lack of production of IgG4 in MVIL-12–vacci-
nated monkeys. Interestingly, the specificity of the antibody
response to MV glycoproteins was altered after vaccination so
that MVIL-12–vaccinated monkeys had an increased response
to the F protein and a decreased response to the H protein,
compared with that of MVtag-vaccinated monkeys. This prob-
ably accounted for the decreased production of neutralizing
antibodies after MVIL-12 vaccination, because antibodies
against H are more potent at neutralizing MV than those against
F [28]. A similar glycoprotein-specific effect was evident in
recipients of a DNA vaccine against respiratory syncytial virus
(RSV), where the addition of IL-12 decreased the RSV attach-
ment glycoprotein (G)–specific antibody response and im-
proved the RSV F-specific response [34]. This suggests that
production of antibody to MV H or RSV G is more dependent
on Th2 cytokines than is production of antibody to F.
Suppression of IL-12 production by macrophages and den-
dritic cells, as observed in previous studies [13, 35], has been
postulated to play a role in the Th2 skewing of the cytokine
profile during MV infection. Altered IL-12 synthesis by neu-
trophils, another source of immunomodulatory cytokines, may
also be involved in the switch to Th2 cytokine production
during measles [11]. The MVIL-12 virus was designed, in part,
with the intent of determining whether the restoration of IL-
12 production could ameliorate immunosuppression during
MV infection, which includes the inhibition of delayed-type
hypersensitivity responses in vivo and a decrease in lymphocyte
proliferation to mitogens in vitro.
The present study has shown that IL-12 may not be suf-
ficient to correct the deficit in T cell proliferative responses
to mitogens observed in vitro after MV infection, a finding
that confirms previous observations by Gans et al. [36] and
that may be explained by a new and interesting observation
potentially associated with MV immunosuppression—a sus-
tained increase in IL-10 levels during convalescence [37]. IL-
10 is an immunomodulatory cytokine known to have similar
effects as MV on autoimmune diseases and latent infections,
such as Crohn disease, nephrotic syndrome, and juvenile
rheumatoid arthritis [38–40].
The specific levels of IL-12 produced in MVIL-12– and MVtag-
vaccinated monkeys are unknown, although the amount of cir-
culating IL-12 was generally higher (compared with baseline) in
the MVIL-12–vaccinated monkeys than the MVtag-vaccinated
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monkeys. The p40 and p35 genes of IL-12 were inserted between
the H and L genes of MVtag to avoid excessive IL-12 production.
MV transcribes genes sequentially, resulting in a gradient of
mRNAs and thus virally expressed proteins. Consequently, gene
products, such as p40 and p35, in MVIL-12 are not produced
in as large quantities as are more upstream gene products.
Nonetheless, changes in the humoral and cellular responses
indicate that IL-12 levels in MVIL-12–vaccinated monkeys were
sufficient to have a biologic effect. Therefore, it is unlikely that
further increasing the production of IL-12 during MV repli-
cation would provide benefit.
In summary, use of an MVIL-12 recombinant virus affected
the specificity and biological activity of the antibody response to
MV by decreasing neutralizing antibody responses, anti-H an-
tibody production, and the MV-specific IgG4 response while
increasing MV-specific anti-F responses. These effects were as-
sociated with an alteration of the Th2 bias of the immune re-
sponse typically associated with MV infection. Manifestations of
MV-associated immunosuppression, such as decreased in vitro
lymphoproliferative responses and lymphopenia, remained un-
affected, suggesting that IL-12 suppression is not the sole factor
in MV-induced immunosuppression.
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